Sign in Subscribe

Archive

A collection of 715 issues

Latest

Jemperli Shows Sustained Response in dMMR/MSI-H Rectal Cancer

Skip to content The CRC Digest Jemperli Shows Sustained Response in dMMR/MSI-H Rectal Cancer Phase 2 data support potential organ preservation in patients with mismatch repair deficient tumors. (Fierce Pharma) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026

CRC Research Finding

Skip to content The CRC Digest ◇ Furin Protein Sustains Tumor Signals in KRAS- and BRAF-Mutated Colorectal Cancer Preclinical research identifies Furin as a key mediator of the TGF-β1-COX-2 pathway in KRAS- and BRAF-mutant colorectal cancer; blocking Furin suppressed tumor growth and enhanced sensitivity to chemotherapy in organoid models. (Oncogene) This

CRC Research Update — July 12, 2026

Today's colorectal cancer research highlights

Y-linked RNA helicase DDX3Y may act as tumor suppressor in male colorectal cancer

Skip to content The CRC Digest Y-linked RNA helicase DDX3Y may act as tumor suppressor in male colorectal cancer First evidence shows DDX3Y, a Y chromosome gene, is downregulated in male CRC tumors and may help explain why men experience higher incidence, metastasis, and mortality rates. (Biochemical Genetics) This content

Ohio study compares risk factors between early-onset and late-onset colorectal cancer

Skip to content The CRC Digest Ohio study compares risk factors between early-onset and late-onset colorectal cancer Researchers examined demographic, lifestyle, and clinical risk factors that differ between patients diagnosed before age 50 versus those diagnosed at 50 or older. (Cancer Causes & Control) This content is informational only and

Prolonged diagnostic delays linked to advanced-stage presentation in early-onset CRC in Mexico

Skip to content The CRC Digest Prolonged diagnostic delays linked to advanced-stage presentation in early-onset CRC in Mexico (Cureus) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

CRC Research Finding

Skip to content The CRC Digest ◇ Systematic review examines Fusobacterium nucleatum as predictor of treatment response A systematic review evaluated whether Fusobacterium nucleatum, a bacterium implicated in CRC progression and immune modulation, can predict treatment response, though its role as a biomarker remains unclear. (Cancer Treatment Reviews) This content is

This Week in CRC Research — July 12, 2026

Weekly colorectal cancer research intelligence

Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer — ESMO Gastrointestinal Oncology The REPROGRAM-01 single-arm phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer. This approach aims to improve outcomes in heavily pre-treated patients

Testing immunotherapy combination in MSS metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. Most colorectal cancers are MSS/pMMR and don't respond well to